January 26, 2018
Can we do more?
Results of recent cardiovascular outcome studies
have shown significant reductions in cardiovascular
disease and overall mortality using sodium–
glucose cotransporter-2 inhibitors and glucagonlike
peptide-1 receptor agonists and have made us
rethink our choices of pharmacotherapy. These
agents should now be considered earlier in the
management of patients with type 2 diabetes to
reduce cardiovascular risk, particularly in those
with existing cardiovascular disease.
